SCHEMBL255442

SCHEMBL255442

Cn1cc(-n2ccc(=O)c(Cc3cccc(NC(=O)OC(C)(C)C)c3)n2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 3/20 0.40
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.38
NPY1R P25929 1/20 0.38
CCKBR P32239 1/20 0.38
MAPK14 Q16539 1/20 0.37
F2RL3 Q96RI0 1/20 0.37
AURKA O14965 1/20 0.37
RPS6KB1 P23443 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
PARP1 P09874 2/20 0.37
HDAC3 O15379 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
SCD O00767 1/20 0.36
AKT1 P31749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13465733 0.91 MET (0.40) SIRT2PARP1
SCHEMBL13274842 0.90 PARP1 (0.40) RORCSIRT2PARP1
SCHEMBL13449334 0.89 GSK3B (0.39) RORCGSK3BDYRK1ACCKBRMAPK14
SCHEMBL13465435 0.89 PARP1 (0.49) SIRT2PARP1
SCHEMBL12516693 0.88 ELANE (0.34) RORCGSK3BDYRK1ASIRT2NPY1R
SCHEMBL13465736 0.88 MGLL (0.45) PARP1
SCHEMBL13274758 0.88 PARP1 (0.38) PARP1
SCHEMBL13275115 0.87 PARP1 (0.39) CYP3A4CYP2C19PARP1
SCHEMBL12517697 0.87 PARP1 (0.38) AURKAPARP1
SCHEMBL165695 0.87 PARP1 (0.40) SIRT2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158041-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2013-06-20 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
WO-2012030633-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 RORC 961/4885GSK3B 301/4885DYRK1A 327/4885
US-20130158041-A1 Tyrosine Kinase Inhibitors MET, ABL1, ERBB2 RORC 1138/4885GSK3B 333/4885DYRK1A 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.